BBLG
Income statement / Annual
Last year (2023), Bone Biologics Corporation's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Bone Biologics Corporation's net income was -$8.95 M.
See Bone Biologics Corporation’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$50.00 |
$96.00 |
$96.00 |
$700.00 |
$4,451.00 |
$877,776.00 |
| Gross Profit |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
-$50.00 |
-$96.00 |
-$96.00 |
-$700.00 |
-$4,451.00 |
-$877,776.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$6.91 M
|
$1.58 M
|
$82,044.00
|
$340,672.00
|
$1.10 M
|
$104,490.00
|
-$1.19 M
|
$11.60 M
|
$3.67 M
|
$623,522.00
|
| General & Administrative
Expenses |
$2.52 M
|
$2.09 M
|
$1.02 M
|
$484,342.00
|
$1.35 M
|
$2.69 M
|
$3.82 M
|
$6.25 M
|
$8.33 M
|
$1.51 M
|
| Selling & Marketing
Expenses |
$2.52 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$2.52 M
|
$2.09 M
|
$1.02 M
|
$484,342.00
|
$1.35 M
|
$2.69 M
|
$3.82 M
|
$6.25 M
|
$8.33 M
|
$1.51 M
|
| Other Expenses |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$104,490.00 |
$2.63 M |
$0.00 |
$0.00 |
-$9,624.00 |
| Operating Expenses |
$9.43 M |
$3.67 M |
$1.10 M |
$825,014.00 |
$2.45 M |
$2.79 M |
$2.63 M |
$17.85 M |
$12.00 M |
$3.01 M |
| Cost And Expenses |
$9.43 M |
$3.67 M |
$1.10 M |
$825,014.00 |
$2.45 M |
$2.79 M |
$2.63 M |
$17.85 M |
$12.00 M |
$3.01 M |
| Interest Income |
$1,868.00 |
$731.71 |
$805.11 |
$998.08 |
$975.77 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$0.00 |
-$2.18 M |
$805,109.00 |
$998,076.00 |
-$975,774.00 |
$1.23 M |
$4.42 M |
$3.17 M |
$1.87 M |
$1.40 M |
| Depreciation &
Amortization |
$9.43 M
|
$3.67 M
|
$1.10 M
|
$50.00
|
$50.00
|
$96.00
|
$96.00
|
$700.00
|
$4,451.00
|
$280.00
|
| EBITDA |
$479,572.00
|
-$4.40 M
|
-$1.10 M
|
-$825,014.00
|
-$2.45 M
|
-$2.38 M
|
-$2.63 M
|
-$17.85 M
|
-$11.99 M
|
-$3.02 M
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$479,572.00
|
$2.18 M
|
-$507,609.00
|
-$998,076.00
|
-$975,774.00
|
-$408,294.00
|
-$4.42 M
|
-$4,862.00
|
-$1.87 M
|
-$9,624.00
|
| Income Before Tax |
-$8.95 M |
-$1.48 M |
-$1.61 M |
-$1.82 M |
-$3.42 M |
-$4.43 M |
-$7.05 M |
-$21.03 M |
-$13.87 M |
-$4.42 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
-$9,428.30 |
-$2.18 M |
$1,600.00 |
$1,600.00 |
$1,603.00 |
$1,729.00 |
$1,600.00 |
$2,243.00 |
$8,840.00 |
$1,600.00 |
| Net Income |
-$8.95 M |
$695,933.00 |
-$1.61 M |
-$1.82 M |
-$3.42 M |
-$4.43 M |
-$7.05 M |
-$21.03 M |
-$13.88 M |
-$4.42 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-34.03 |
14.62 |
-85.11 |
-150.43 |
-281.85 |
-66.12 |
-135.84 |
-419.13 |
-365.67 |
-103.02 |
| EPS Diluted |
-34.01 |
14.62 |
-85.11 |
-150.43 |
-281.85 |
-66.12 |
-135.84 |
-419.13 |
-365.67 |
-103.02 |
| Weighted Average Shares
Out |
$263,000.00
|
$47,596.00
|
$18,924.00
|
$12,130.00
|
$12,151.00
|
$67,009.00
|
$51,910.00
|
$50,174.00
|
$37,949.00
|
$42,949.00
|
| Weighted Average Shares
Out Diluted |
$263,137.00
|
$47,596.00
|
$18,924.00
|
$12,130.00
|
$12,151.00
|
$67,009.00
|
$51,910.00
|
$50,174.00
|
$37,949.00
|
$42,949.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
